ArticlePharmaceutics2020
Characteristic of K3 (CpG-ODN) as a Transcutaneous Vaccine Formulation Adjuvant.
Sayami Ito et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
10 papers cite it
this papertrialcites it
ArticlePharmaceutics2020
Sayami Ito et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.